期刊
BIOCHEMICAL PHARMACOLOGY
卷 194, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2021.114815
关键词
Synovial fibroblast; Drug target; Rheumatoid arthritis; Inflammation; Signal transduction; Apoptosis
资金
- Ministerio de Ciencia, Innovacion y Universidades, Spain, FEDER [SAF2017-85806-R]
Synovial cells, especially activated synovial fibroblasts, are key players in joint destruction in rheumatoid arthritis. Identifying SF phenotypes, controlling epigenetic changes, and modulating cellular functions are promising approaches to develop novel therapeutic targets for preserving joint architecture and function in RA. Further research is needed to determine the most relevant targets for drug development.
Synovial cells play a key role in joint destruction during chronic inflammation. In particular, activated synovial fibroblasts (SFs) undergo intrinsic alterations leading to an aggressive phenotype mediating cartilage destruction and bone erosion in rheumatoid arthritis (RA). Recent research has revealed a number of targets to control arthritogenic changes in SFs. Therefore, identification of SF phenotypes, control of epigenetic changes, modulation of cellular functions, or regulation of the activity of cation channels and different signaling pathways has been investigated. Although many of these approaches have shown efficacy in vitro and in animal models of RA, further research is needed to select the most relevant targets for drug development. This review is focused on the role of SFs as a potential strategy to discover novel therapeutic targets in RA aimed at preserving joint architecture and function.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据